Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
Date:9/21/2009

n archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
2. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
3. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
4. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
5. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
6. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
9. Keryx Biopharmaceuticals Receives Nasdaq Notification
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Offers Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at an ... ... Los Angeles, CA (PRWEB) December 16, 2009 -- Actively healthy ... in all natural skin care for their children as ... children featuring the beloved artwork of The Very Hungry Caterpillar ...
(Date:12/16/2009)... direct link has been found, , , WEDNESDAY, Dec. 16 ... commonly linked to food poisoning and the stomach pain ... cause of some urinary tract infections. , Researchers have ... from stores and restaurants and in women with the ... were transmitted directly to the women through the food ...
(Date:12/16/2009)... promote Massachusetts companies through annual marketing campaign , ... ... BioSpace unveiled the 2010 Genetown™ Hotbed Campaign as ... , ,Genetown is sponsored by MassBio and showcases ... The campaign places each entity’s brand on an electronic ...
(Date:12/16/2009)... government report shows, , , WEDNESDAY, Dec. 16 (HealthDay News) ... reached almost 78 years, a record high, federal health ... can expect to live to 80.4 years on average ... from the U.S. Centers for Disease Control and Prevention. ... live longer than their parents, life expectancy in the ...
(Date:12/16/2009)... Dec. 16 Medical travel facilitator Companion ... in Puerto Rico into its network of international ... lower than those at mainland U.S. facilities. ,, ... medical travel assistance and preferred pricing for its ... treatment at either HIMA San Pablo Bayamon or ...
Breaking Medicine News(10 mins):Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:Thriving Bioscience Region Leaves Its Mark 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2
... Ill., Feb. 25 Omron Healthcare, Inc. ... chief operating officer. With,an extensive background in ... sales and profit growth in their mainstay ... and professional medical. Kondraske,s experience as a ...
... CHARLOTTESVILLE, Va., Feb. 25 Meddius, an ... will,provide integration technology and professional services to ... control system,which provides hospitals with a Web-based, ... healthcare associated infections (HAIs). The announcement,was made ...
... chain management system enhanced to support multifaceted hospital, environments; ... ... ORLANDO, Fla., Feb. 25 HIMSS ,08 -- ... system solutions to acute,healthcare facilities, today introduced its OptiFlex(TM) ...
... Platform helps hospitals automate charity care, ... Form 990, CHICAGO, Feb. 25 The ... the process that assists,hospitals in determining whether a ... addresses many of Ohio Attorney General Marc Dann,s,concerns ...
... PORTLAND, Ore., Feb. 25 The Food ... cancer of the colon and,lungs. In off-label use, ... that,s currently used by some doctors to treat ... neck, pancreatic, ovarian,and hepatocellular., Some ophthalmologists are ...
... According to leading weight loss,expert, Dr. Kent Sasse, ... actually cause more weight gain. Insulin, the primary,treatment for ... patients,in part because insulin acts on the fat storage ... these fats., Diabetes mellitus is one of the ...
Other Medicine News:Health News:Omron Healthcare Names New Chief Operating Officer Bob Kondraske 2Health News:Meddius Signs Agreement to Deliver an Integration Platform for Premier's SafetySurveillor(TM) 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 3Health News:TransUnion Addresses Ohio Attorney General's Concerns Surrounding Non-Profit Tax-Exempt Status 2Health News:TransUnion Addresses Ohio Attorney General's Concerns Surrounding Non-Profit Tax-Exempt Status 3Health News:Off-Label Avastin Use for Wet Macular Degeneration 2Health News:Off-Label Avastin Use for Wet Macular Degeneration 3Health News:Cure Diabetes with Weight Loss, Not Drugs, Expert Says 2
(Date:12/16/2009)... N.Y., Dec. 16 BioSpecifics Technologies Corp. ... first in class collagenase-based products, today announced top-line ... clinical trial of XIAFLEX(TM) for the treatment of ... presence of inelastic collagen on the shaft of ... make sexual intercourse difficult or impossible in advanced ...
(Date:12/16/2009)... 16 Vivakor, Inc. (OTC Bulletin ... agreement with Baker Consulting out of Walnut ... Group, Inc. out of South Florida. ... to assist with business development, financing and ... acquisition strategy. Specifically, Baker Consulting is exploring ...
(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4Vivakor Signs Business Development Agreement With Baker Consulting 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Hoarseness predominates in vocal health issues for inner city children 58831 1Designing drugs and their antidotes together improves patient care 58829 1Designing drugs and their antidotes together improves patient care 58829 2Designing drugs and their antidotes together improves patient care 58829 3Global death toll 3A 1 million premature babies every year 58827 1Global death toll 3A 1 million premature babies every year 58827 2Global death toll 3A 1 million premature babies every year 58827 3Global death toll 3A 1 million premature babies every year 58827 4
... - ZIOPHARM Oncology, Inc.,(NASDAQ: ZIOP) announced today that ... the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference on ... the Mandarin Oriental Hotel, New York. Dr. Lewis,will ... update on its,clinical development programs., The presentation will ...
... -- Micromet,Inc. , a biopharmaceutical company focusing on ... inflammatory,and autoimmune diseases, today announced that Dr. Christian ... will,present at the 3rd Annual C.E. Unterberg, Towbin ... 12, 2007 at 10:00am,eastern. , A webcast of ...
Other Medicine Technology:ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin,Emerging Growth Conference 2
Histopathology Reference Laboratory provides a full range of histology services, encompassing routine and specialized grossing, processing, embedding, microtomy, routine and special staining and cove...
PhenoPath Laboratories provides screening, diagnostic, and prognostic testing services to hospitals, physician offices, surgery centers, biopharmaceutical companies and research institutions nationwi...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
Medicine Products: